Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacillus coagulans for aGVHD prevention
NCT06593834Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- Live Biotherapeutic Products
01
Overview
Randomised trial of bacillus coagulans in Acute Graft-Versus-Host Disease (aGvHD) (2 arms). Primary endpoint: Rate of acute graft-versus-host disease at 100 days. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
bacillus coagulans
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06593834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593834.